Short answer
4D Molecular Therapeutics, Inc. (FDMT) filed its Q3 2025 10-Q quarterly report on Nov 10, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $90,000 (up 2900.0% year over year) with net income of −$57M.
Q3 2025 key financials · XBRL
- Revenue
- $90,000
- +2900.0% YoY · +500.0% QoQ
- Net income
- −$57M
- −29.7% YoY · −4.1% QoQ
- Operating margin
- -67983.3%
- EPS (diluted)
- −$1.01
- −27.8% YoY · −3.1% QoQ
Source: XBRL data from the 4D Molecular Therapeutics, Inc. (FDMT) Q3 2025 10-Q on SEC EDGAR. USD.
4D Molecular Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $90,000, up 2,900% YoY from $3,000, entirely from CFF collaboration payments
- Operating margin -67983.3% vs -1704400.0% YoY; net loss $56.9M vs $43.8M
- R&D expenses $49.4M, up 28% YoY, driven primarily by 4D-150 clinical trial costs
- Cash, equivalents and marketable securities $372.2M at September 30, 2025
- $93.3M net proceeds from November offering; management expects funding for at least one year
Risk Factors
- No newly added or changed risk factors identifiable; filing text states no explicit comparison with the prior 10-K
- Recurring net losses of $56.9 million in Q3 2025 and accumulated deficit of $735.7 million
- Novel AAV genetic medicines face evolving FDA, EMA, CAT, IBC and IRB requirements that may delay approval
- No products approved or product revenue generated, increasing dependence on successful ongoing clinical development
- $372.2 million in cash, cash equivalents and marketable securities expected to fund planned operations for at least one year
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other 4D Molecular Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.